Clinical trials: SIRS(Systemic Inflammatory Response Syndrome)
- Condition SIRS(Systemic Inflammatory Response Syndrome)
- Funder type Industry (pharma, biotech, devices)
Sepsis, Acute Lung Injury
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
This Phase I/IIa, multi-center, randomized, placebo-controlled, single-blinded dose-escalation study evaluated TNX-832 (also referred to as ALT-836 and Sunol cH36) in subjects with suspected or proven bacteria-induced ALI/ARDS.
- Conditions
- Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT01438853
- Testing
- TNX-832
- Where
- 7 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Altor BioScience
Sepsis
Clinical Trial to Evaluate MDW for Early Detection of Sepsis
This study is intended to clinically verify Monocyte Distribution Width (MDW) parameter of DxH 900 Hematology Analyzer for use in early detection and risk assessment of sepsis, severe sepsis, and septic shock in critically ill…
- Trial name
- NCT06267742
- Testing
- Complete Blood Count (CBC) with Differential
- Where
- 3 sites in China
- Volunteers
- 2,200 people
- Sponsor
- Beckman Coulter, Inc.
Fungemia, Fungal Infections
A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections
The objective of this study is to compare the efficacy and safety between Mycamine and Itraconazole oral solution in preventing invasive fungal infections on autologous(malignant blood diseases) or allogeneic hematopoietic stem…
- Trial name
- NCT00794703
- Testing
- micafungin (Mycamine), itraconazole
- Where
- 10 sites in China
- Volunteers
- 288 people
- Sponsor
- Astellas Pharma Inc
Hypotension
Efficacy Study of a Facemask Device to Treat Hypotension
The purpose of this study is to determine if the impedance threshold device (ITD) attached to a facemask can increase blood pressure in patients who present to the emergency department with hypotension secondary to hypovolemia.
- Trial name
- NCT00256724
- Testing
- Impedance Threshold Device
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Advanced Circulatory Systems
Sepsis
Biomarker-enhanced Artificial Intelligence Based Pediatric Sepsis Screening Tool
The overall objective of this proposed research is the derivation of a biomarker-enhanced artificial intelligence (AI)-based pediatric sepsis screening tool (PSCT) (software) that can be used in combination with the hospital's…
- Trial name
- NCT05311046
- Testing
- Pediatric sepsis screening tool (either algorithmic or manual)
- Where
- United States
- Volunteers
- 12,961 people
- Sponsor
- Computer Technology Associates, Inc.
Acute Kidney Injury Due to Sepsis
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting…
- Trial name
- CLEAR-AKI (NCT05996835)
- Testing
- TIN816 70 mg lyophilisate powder
- Where
- 79 sites in United States, Argentina and 15 more
- Volunteers
- 316 people
- Sponsor
- Novartis Pharmaceuticals
Blood Stream Infection, Blood Stream Infections
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
This study is designed to evaluate the clinical performance of the UllCORE Bloodstream Infection (BSI) Test, an investigational molecular diagnostic test intended to detect microorganisms and selected antimicrobial resistance…
- Conditions
- Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia
- Trial name
- B-RAPID (NCT07859852)
- Testing
- UllCORE BSI Test
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 1,500 people
- Sponsor
- Deepull Diagnostics S.L.
Cytokine Release Syndrome in COVID-19-induced Pneumonia
Canakinumab MAP in COVID-19 Pneumonia With CRS
This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia
- Trial name
- NCT04476706
- Testing
- canakinumab
- Sponsor
- Novartis Pharmaceuticals
Shock, Septic
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of nangibotide versus placebo in adult patients…
- Trial name
- NCT03158948
- Testing
- Nangibotide 0.3 mg/kg, Nangibotide 1 mg/kg, Nangibotide 3 mg/kg
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Inotrem
Bacterial Infections
Evaluation of the Artificial Intelligence-based Prescription Support Software iAST® for the Choice of Empirical and Semi-targeted Antibiotic Treatment
Inadequate treatment of infections frequently leads to complications that cause new visits to the doctor, lengthen hospital stays and can lead to sepsis, even causing the death of affected patients.
- Trial name
- EVIAST (NCT06174519)
- Testing
- Medical device simulation
- Where
- Spain
- Volunteers
- 325 people
- Sponsor
- Pragmatech AI Solutions
Sepsis, Septic Shock
Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis
One of the significants health problems in the world is sepsis, with the number of cases reaching 20-30 million per year, according to the WHO.
- Trial name
- NCT06602245
- Where
- 4 sites in Russia
- Volunteers
- 30 people
- Sponsor
- Efferon JSC
Candidemia
Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)
The purpose of this study is to validate clinical performance (i.e. estimated sensitivity and specificity) of the T2 Candida test on the T2 DX Instrument compared to blood culture results and/or known Candida positive status of…
- Trial name
- direcT2 (NCT01752166)
- Where
- 8 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- T2 Biosystems
Shock, Systemic Inflammatory Response Syndrome
Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)
To determine the safety and effectiveness of pyridoxylated hemoglobin polyoxyethylene conjugate (PHP) administered by continuous intravenous (IV) infusion in systemic inflammatory response syndrome (SIRS) patients with shock.
- Trial name
- NCT00021502
- Testing
- pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)
- Volunteers
- 1,000 people
- Sponsor
- Apex Bioscience
Sepsis, Bacteriemia
Safety and Efficacy of Immages System in Patients Recieving IV Therapy
The study will evaluate the functionality of IMMAGES , an intravenous infusion device system, in patients hospitalized in Bait Balev hospital.
- Conditions
- Sepsis, Bacteriemia, CHF
- Trial name
- IV (NCT02020811)
- Testing
- Sentinel
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- PRo-IV
Invasive Candidiasis, Candidemia
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
- Trial name
- NCT00189709
- Testing
- Micafungin, fluconazole
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Hepatitis B Infection, Congenital Malformation
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission
Immunoprophylaxis with two hepatitis B vaccinations following the hepatitis B immune globulin (HBIg) and hepatitis B vaccine at birth is largely effective in protecting infants from hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia
- Trial name
- NCT03476083
- Testing
- Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
- Where
- 7 sites in China
- Volunteers
- 280 people
- Sponsor
- New Discovery LLC
Toxic-Shock Syndrome, Sepsis
Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02971670
- Testing
- rTSST-1 Variant Candidate Vaccine
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Sepsis Associated Disseminated Intravascular Coagulation (DIC)
A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.
This study is designed to evaluate a new investigational drug, BAY 3389934, in healthy Japanese volunteers. The primary purpose is to see how safe the drug is and how well it is tolerated by the body when given at different…
- Trial name
- NCT07176728
- Testing
- BAY 3389934
- Where
- 2 sites in Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Severe Sepsis
Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis
Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.
- Trial name
- NCT00630656
- Testing
- Talactoferrin alfa
- Where
- 34 sites in United States, Canada and 3 more
- Volunteers
- 190 people
- Sponsor
- Agennix
Acute Pancreatitis With Uninfected Necrosis, Unspecified
Hemoperfusion Efferon СT for the Treatment of Patients With Acute Pancreatitis
Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF).
- Trial name
- NCT05695001
- Testing
- Efferon CT
- Where
- Russia
- Volunteers
- 34 people
- Sponsor
- Efferon JSC